CYTR CytRx Corporation

0.47
-0.03  -5%
Previous Close 0.49
Open 0.5
Price To Book 0.71
Market Cap 15738987
Shares 33,637,501
Volume 154,083
Short Ratio
Av. Daily Volume 155,873

SEC filingsSee all SEC filings

  1. 8-K - Current report 181209057
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181156205
  3. 8-K - Current report 181013472
  4. 8-K - Current report 181009235
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18993408

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 poster at ASCO June 4, 2017. Abstract 11051.
Aldoxorubicin
Advanced sarcomas - cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 completed.
Aldoxorubicin
Cancer - AIDS-related Kaposi’s sarcoma
Phase 2 trial completed.
Aldoxorubicin
Cancer - unresectable glioblastoma
Phase 2b data due 2Q 2017 according to 1Q guidance. No mention in 2Q earnings report. MIA.
Aldoxorubicin
Relapsed/refractory small cell lung cancer
Phase 1b dosing initiated February 2018.
Aldoxorubicin
Squamous Cell Carcinoma

Latest News

  1. CytRx Corporation to Present at the 11th Annual LD Micro Main Event
  2. Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments
  3. Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT
  4. Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
  5. Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
  6. CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
  7. CytRx: 3Q Earnings Snapshot
  8. CytRx Corporation Reports Third Quarter 2018 Financial Results
  9. Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
  10. CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
  11. Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT
  12. CytRx Corporation to Present at the 2018 MicroCap Conference
  13. CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
  14. CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
  15. CytRx Corporation to Host Earnings Call
  16. CytRx Corporation Reports Second Quarter 2018 Financial Results
  17. CytRx Corporation Pays Off Balance of Outstanding Debt
  18. CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
  19. CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application

SEC Filings

  1. 8-K - Current report 181209057
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181156205
  3. 8-K - Current report 181013472
  4. 8-K - Current report 181009235
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18993408
  6. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 18960169
  7. DEF 14A - Other definitive proxy statements 18939463
  8. 8-K - Current report 18913789
  9. 8-K - Current report 18877776
  10. 8-K - Current report 18838328